Active	Status	Sponsor type	Region	Phase	Filter
5 Active 7 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
osanetant (ACER-801) / Sanofi, Zevra Therap
NCT05325775: Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause	Completed	1/2	49	US	ACER-801 50 mg BID, osanetant, ACER-801 100 mg BID, ACER-801 200 mg BID, Placebo, Placebo of ACER-801	Acer Therapeutics Inc.	Post-menopausal Vasomotor Symptoms	03/23	03/23
PORT-MAP, NCT05607342: Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate	Terminated	1	1	US	Osanetant	University of Kansas Medical Center	Prostate Adenocarcinoma	09/23	11/23
POSH-MAP, NCT05647447: Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate	Withdrawn	1	10	US	Osanetant	University of Kansas Medical Center	Prostate Adenocarcinoma	09/23	10/23
Edsivo (celiprolol) / Zevra Therap
2015-000207-13: Chronic beta-blockade and cardiopulmonary exercise in Chronic Obstructive Pulmonary Disease	Not yet recruiting	4	10	Europe	Bisoprolol 2.5mg tablets, Celiprolol 200mg tablets, Tablet	Tayside Clinical Trials Unit, University of Dundee, TENOVUS Scotland	Chronic Obstructive Pulmonary Disease (COPD), 'Chronic bronchitis' 'Smoker's lung' 'Emphysema', Diseases [C] - Respiratory Tract Diseases [C08]
DiSCOVER, NCT05432466: Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome	Recruiting	3	150	US	ACER-002 (celiprolol) 200 mg BID, ACER-002, celiprolol, Placebo BID, placebo	Acer Therapeutics Inc.	Vascular Ehlers-Danlos Syndrome	03/29	04/29

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
osanetant (ACER-801) / Sanofi, Zevra Therap
NCT05325775: Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause	Completed	1/2	49	US	ACER-801 50 mg BID, osanetant, ACER-801 100 mg BID, ACER-801 200 mg BID, Placebo, Placebo of ACER-801	Acer Therapeutics Inc.	Post-menopausal Vasomotor Symptoms	03/23	03/23
PORT-MAP, NCT05607342: Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate	Terminated	1	1	US	Osanetant	University of Kansas Medical Center	Prostate Adenocarcinoma	09/23	11/23
POSH-MAP, NCT05647447: Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate	Withdrawn	1	10	US	Osanetant	University of Kansas Medical Center	Prostate Adenocarcinoma	09/23	10/23
Edsivo (celiprolol) / Zevra Therap
2015-000207-13: Chronic beta-blockade and cardiopulmonary exercise in Chronic Obstructive Pulmonary Disease	Not yet recruiting	4	10	Europe	Bisoprolol 2.5mg tablets, Celiprolol 200mg tablets, Tablet	Tayside Clinical Trials Unit, University of Dundee, TENOVUS Scotland	Chronic Obstructive Pulmonary Disease (COPD), 'Chronic bronchitis' 'Smoker's lung' 'Emphysema', Diseases [C] - Respiratory Tract Diseases [C08]
DiSCOVER, NCT05432466: Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome	Recruiting	3	150	US	ACER-002 (celiprolol) 200 mg BID, ACER-002, celiprolol, Placebo BID, placebo	Acer Therapeutics Inc.	Vascular Ehlers-Danlos Syndrome	03/29	04/29